MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall ...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML
THURSDAY, April 21, 2022 -- Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 21, 2022 Category: Pharmaceuticals Source Type: news

Machine Learning Approach to Classification of Acute Leukemias Machine Learning Approach to Classification of Acute Leukemias
Using key flow cytometry parameters, the authors developed a machine learning model to classify acute leukemias and distinguish them from non-neoplastic cytopenias.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Biomarker Predicts Nonresponse to CAR T in Pediatric ALL Biomarker Predicts Nonresponse to CAR T in Pediatric ALL
Alternative strategies could be offered to children and young adults with advanced acute lymphoblastic leukemia (ALL) identified as being unlikely to respond to the expensive therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Episode 2: Good-Risk Acute Myeloid Leukemia Episode 2: Good-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Gautam Borthakur discuss good-risk acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia
Drs Gail Roboz and Farhad Ravandi discuss acute promyelocytic leukemia, a relatively uncommon subset of acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL
TUESDAY, April 12, 2022 -- For patients with acute lymphoblastic leukemia with resistance to C19 CAR T-cell therapy, resistance mechanisms that can be detected prior to treatment have been identified, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news

Africa: First Case of HIV Cure in a Woman After Stem Cell Transplantation Reported At CROI-2022
[WHO] The International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1107 reported the first case of HIV cure in a woman living with HIV submitted to a dual stem cell transplant (i.e., an umbilical cord blood transplant combined with a half-matched bone marrow transplant) for treatment of an acute myelogenous leukemia. The IMPAACT P1107 researchers presented the case details during the oral abstract session held at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 202 (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 4, 2022 Category: Infectious Diseases Source Type: news

Survival Up With Bortezomib in T - Cell Lymphoblastic Lymphoma
No differences in EFS or OS seen with/without bortezomib overall or in patients with T - cell acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 25, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Radiology, Journal, Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
Most disparities in acute myeloid leukemia mortality death accounted for by census tract measures (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 23, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
WEDNESDAY, March 23, 2022 -- For patients with acute myeloid leukemia (AML), non-Hispanic Black individuals have inferior survival to non-Hispanic White individuals, with census tract measures accounting for most of the disparities in survival,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2022 Category: Pharmaceuticals Source Type: news

TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland, March 17, 2022 -- (Healthcare Sales & Marketing Network) -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "... Biopharmaceuticals, Oncology, FDA TC Biopharm, T cell therapy, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2022 Category: Pharmaceuticals Source Type: news